CD8A and neoplasm: Although the combined treatment induced antitumor immunity, the therapy led to minimal tumor clearance, possibly due to its limited ability to overcome T cell tolerance and drive potent tumor-specific CD8+ T cell responses in well-established immunosuppressive tumor microenvironments (TME) [18–20].